McGill Laboratory Biosafety Manual - Second Edition, 1997
3 Classification of Pathogens
3.1 Conventional Pathogens
Criteria for classification of infectious agents are outlined in the document
"Laboratory Biosafety Guidelines", published jointly by Health Canada's
Laboratory Centre for Disease Control and the Medical Research Council
of Canada (refer to Section 12, "Suggested Reading"). Essentially, microbiological
pathogens are classified according to their impact upon the individuals
who manipulate them, upon their colleagues, and upon the surrounding community.
Agents which pose little or no risk are assigned to Risk Group 1, while
those with the greatest hazardous potential are in Risk Group 4. Risk assessment
is based upon several factors, including:
-
severity of induced disease
-
route(s) of infection
-
virulence and infectivity of the microorganism
-
antibiotic resistance patterns
-
availability of effective medical treatment (e.g., antibiotic therapy)
or vaccine
-
presence of vectors (e.g., arthropods)
-
whether the pathogen is indigenous to Canada
-
possible effects on other animals and plants
Before setting up experiments involving new biohazards, consideration should
also be given to conditions under which the infectious agent is used. For
example, manipulation of large volumes and high concentrations of an infectious
microorganism in culture media presents a greater risk than smearing the
same pathogen on a slide. Work involving release of microbial aerosols,
passage in animals and infection of arthropod vectors also increase the
hazard. In these cases, pathogens should be handled as if they were in
the next highest risk group: i.e., if the experimental procedure is likely
to generate large amounts of aerosolized Risk Group 2 agent, the physical
and operational requirements applicable to Risk Group 3 agents should be
observed.
An outline of the characteristics of agents in each Risk Group is presented
in Table 1. A comprehensive listing of the pathogens in each Risk Group
can be found in "Laboratory Biosafety Guidelines".
Table 1 - Risks and characteristics associated with
pathogens from Risk Groups 1 to 4, and recommended containment level and
class of biological safety cabinet
| Risk Group |
Risk Assessment |
Characteristics |
Examples |
Containment Level |
Biological Safety Cabinet |
| 1 |
low individual
low community
|
unlikely to cause disease in animals or humans
|
Lactobacillus spp.,Bacillus subtilis, Naegleria
gruberi, Micrococcus spp., E. coli K12 |
1 |
Not required |
| 2 |
moderate individual
low community
|
rarely cause serious human or animal disease
effective prevention and treatment available
limited risk of spreading
|
Hepatitis B virus, Toxoplasma spp., HIV (non-cultured),
Ascaris, Salmonella typhimurium |
2 |
Class I or Class II |
| 3 |
high individual
low community
|
may cause serious disease in humans or animals
effective prevention and treatment available
unlikely to be spread by casual contact
|
Lassa fever virus, Hantavirus, Yersinia pestis, Histoplasma
capsulatum, Bacillus anthracis, cultured isolates of HIV* |
3 |
Class I or Class II |
| 4 |
high individual
high community
|
likely to cause very serious disease in humans or animals,
readily transmitted from one individual to another, or between animals
and humans
preventative vaccines or effective treatment not available
|
Marburg virus, Ebola virus, Crimean-Congo hemorrhagic fever
virus,
Herpesvirus simiae |
4 |
(Class I or II plus positive pressure suits) or Class
III |
*Containment Level 2 facilities and Level 3 operational requirements
can be used for procedures involving viral isolation and identification.
For production activities, use Level 3 physical and operational requirements.
3.2 Unconventional Pathogens ("Slow Viruses")
Some progressive neurological diseases are caused by unconventional "slow
viruses". Among the slow viruses, prions (proteinaceous infectious particles)
have been associated with transmissible degenerative diseases of the central
nervous system in humans (Creutzfeldt-Jacob, kuru) and animals (transmissible
encephalopathy of mink and scrapie in sheep and goats). These unconventional
viruses are resistant to destruction by chemical (10% formalin, glutaraldeyhye,
70% ethanol, iodine) and physical (UV light, ionizing radiation, boiling)
procedures. While there have been no documented cases of laboratory-acquired
infections, the following precautions should be observed when handling
neurological material from infected or potentially infected humans and
animals:
-
handle as Risk Group 2 or higher, depending on the nature of work and amount
of agent being manipulated,
-
handle formalin-fixed tissues and paraffin-embedded blocks as if still
infectious,
-
keep up-to-date on disinfection protocols. Currently recommended procedures
for inactivation procedures include the following choices:
-
autoclave at 132-136°C for 18-60 minutes
-
1N sodium hydroxide for 1 hour, either alone or in combination with autoclaving
at 121°C for 30 minutes
-
1-5% solution of sodium hypochlorite: immerse instruments for 18 hours
or longer; treat work surfaces for at least 30 minutes
-
phenolized formalin (a solution containing 15 g of phenol per dL of 10%
formalin)
-
if skin becomes contaminated, treat for 5-10 minutes with 1N sodium hydroxide
followed by extensive washing with water
3.3 Genetically Engineered Organisms
The term "biotechnology" describes a variety of techniques for manipulation
of cells; biotechnology has long been used for purposes such as selective
breeding of animals and food production (bread, yogurt, beer).
More recently, in vitro incorporation of segments of genetic material
from one cell into another ("recombinant DNA technology") has resulted
in altered organisms which can manufacture products such as vaccines, hormones,
interferons and enzymes. Genetically engineered organisms are used for
treatment of waste and spills, and plants can be made resistant to cold,
disease, pests and drought.
However, biotechnology carries with it the potential for harm. A genetically
altered organism may be directly pathogenic or toxic or, if released into
the environment, might crowd out beneficial organisms, transfer undesirable
genetic traits to wild species or mutate into a pathogenic form.
The risks associated with recombinant DNA technology are to be assessed
by the investigator when submitting the "Application of Use Biohazardous
Materials" form to the McGill Biohazards Committee (refer to Section 1.2.1,
"The Biohazards Committee"). Such assessments should be based upon the:
-
source of the DNA to be transferred,
-
vector,
-
host.
When assessing the risk of, and containment level required by, a genetic
engineering protocol, the following approach is recommended: if the components
of a genetic manipulation are not hazardous, then the altered organism
is unlikely to present a risk, and no restrictions are needed. However,
if one of the components is potentially hazardous, a risk level appropriate
for the known hazard is assigned and modified as required. Subsequent modifications
depend on factors such as:
-
expression of the transferred gene in the recombinant organism,
-
ability of the vector to survive outside the laboratory,
-
expected interactions between transferred gene, host and other factors.
3.4 Tissue Cultures
Cell cultures derived from humans or animals known to be infected with
a pathogen, as well as cultures known or suspected to contain infectious
microorganisms (e.g., herpesvirus or EBV-transformed cultures) should be
assigned to the risk group appropriate for the suspected or known pathogen
and handled using the relevant containment level and work practices. Risk
groups and containment levels for specific pathogens can be obtained from
the federal "Laboratory Biosafety Guidelines" cited in Section 3.1, "Conventional
Pathogens" above.
In addition, mammalian cell cultures may carry unsuspected oncogenic,
allergenic or infectious particles. It is impractical, if not impossible,
to screen such cultures for all potentially harmful microorganisms: even
well-characterized lines with a history of safe use can become contaminated
by adventitious, possibly infectious, microorganisms. For this reason,
it is prudent to treat all mammalian cultures as moderate risk agents (i.e.,
risk group 2) and to use containment level 2 facilities and work practices
whenever working with them.